December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

212.29 +4.13 (+1.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
News headline image
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Recap: Ligand Pharmaceuticals Q1 Earnings ↗
 
Via Benzinga
News headline image
Ligand Reports First Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗
 
Via Benzinga
News headline image
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Earnings Scheduled For February 22, 2023 ↗
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
News headline image
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
News headline image
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says ↗
Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. 
Via Benzinga
News headline image
Ligand Pharma Issues Mixed Guidance For FY23 ↗
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its... 
Via Benzinga
News headline image
Ligand Provides Highlights from its Investor and Analyst Day Event
From Ligand Pharmaceuticals
Via Business Wire
News headline image
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Hold Investor and Analyst Day on December 13
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Third Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Earnings Outlook For Ligand Pharmaceuticals ↗
Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Ligand Announces Completion of OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Distribution of OmniAb Complete and Business Combination Closed
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Third Quarter Financial Results on November 7
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
OmniAb Business Combination Approved by APAC Shareholders
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.